Galapagos NV (GLPGF)
OTCMKTS · Delayed Price · Currency is USD
34.00
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
Galapagos NV Employees
Galapagos NV had 558 employees as of June 30, 2025. The number of employees decreased by 146 or -20.74% since the number was reported on December 31, 2024.
Employees
558
Change
-146
Growth
-20.74%
Revenue / Employee
$478,186
Profits / Employee
-$726,568
Market Cap
2.22B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 558 | -146 | -20.74% |
| Dec 31, 2024 | 704 | -419 | -37.31% |
| Dec 31, 2023 | 1,123 | -215 | -16.07% |
| Dec 31, 2022 | 1,338 | 29 | 2.22% |
| Dec 31, 2021 | 1,309 | -180 | -12.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Galapagos NV News
- 5 weeks ago - Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities - GlobeNewsWire
- 7 weeks ago - Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation - Seeking Alpha
- 2 months ago - GLPG Crosses Above Average Analyst Target - Nasdaq
- 2 months ago - Galapagos (GLPG) Showcases Promising Phase 2 Results for CAR T-Cell Therapy - GuruFocus
- 2 months ago - Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 - GlobeNewsWire
- 2 months ago - Galapagos Receives Transparency Notifications from Bank of America - GlobeNewsWire
- 3 months ago - RBC Capital Raises Price Target for GLPG to $32. ... - GuruFocus
- 3 months ago - Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript - Seeking Alpha